Crystal Mackall
Stanford University · National Cancer Institute, National Institutes of Health
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Crystal Mackall as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:21 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT03241940 · Study of CD19/CD22 Chimeric Antigen Receptor T Cells in Children & Young Adults w/ Recurrent or Refractory B Cell MalignanciesStanford University · active not recruiting · B Acute Lymphoblastic Leukemia, CD19 Positive, Minimal Residual Disease · principal investigator
- Ph2NCT00001566 · A Pilot Study of Autologous T-Cell Transplantation With Vaccine Driven Expansion of Anti-Tumor Effectors After Cytoreductive Therapy in Metastatic Pediatric SarcomasNational Cancer Institute (NCI) · completed · Ewing's Sarcoma, Rhabdomyosarcoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:21 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 15 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Attacking the Immunopeptidome of Ewing SarcomaU01CA281865 · NCI · STANFORD UNIVERSITY · fiscal years 2023 to 2026 · $697,814 awarded in 2026Same name and institution; not confirmed by an ID
- Cancer ImmunotherapyP30CA124435 · NCI · STANFORD UNIVERSITY · fiscal years 2022 to 2026 · $61,174 awarded in 2026Same name and institution; not confirmed by an ID
- Designing Chimeric Antigen Receptor Therapies to Overcome Treg SuppressionP01CA049605 · NCI · STANFORD UNIVERSITY · fiscal years 2019 to 2026 · $451,962 awarded in 2026Same name and institution; not confirmed by an ID
- Multimodal AI modeling of T cell therapies to predict patient response and nominate advanced cell design strategiesOT2OD038101 · OD · STANFORD UNIVERSITY · fiscal years 2025 to 2026 · $1,681,676 awarded in 2026Same name and institution; not confirmed by an ID
- Next Generation GPC2-CARs for MedulloblastomaUH3CA297747 · NCI · STANFORD UNIVERSITY · fiscal years 2026 · $2,224,191 awarded in 2026Same name and institution; not confirmed by an ID
- Next Generation Immunotherapies for Pediatric CancersR35CA283888 · NCI · STANFORD UNIVERSITY · fiscal years 2024 to 2026 · $932,174 awarded in 2026Same name and institution; not confirmed by an ID
- Developing Safe and Effective GD2-CAR T Cell Therapy for Diffuse Midline GliomasR01CA263500 · NCI · STANFORD UNIVERSITY · fiscal years 2021 to 2025 · $660,052 awarded in 2025Same name and institution; not confirmed by an ID
- Next Generation GPC2-CARs for MedulloblastomaUG3CA297747 · NCI · STANFORD UNIVERSITY · fiscal years 2024 to 2025 · $1,390,720 awarded in 2025Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name in childhood acute lymphoblastic leukemia, ranked by citations from NIH iCite, fetched 2026-11-12 11:21 UTC. The ranking covers the 200 most relevant of 6 PubMed records, and a shared surname and initials can bring in a namesake. All 6 on PubMed
- 2,446 citationsRCR 71.3
- CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy.Nat Med · 20181,142 citationsRCR 36.1
- CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial.J Clin Oncol · 2020378 citationsRCR 15.0
- Long-Term Follow-Up of CD19-CAR T-Cell Therapy in Children and Young Adults With B-ALL.J Clin Oncol · 2021306 citationsRCR 15.4
- Systematic Evaluation of Neurotoxicity in Children and Young Adults Undergoing CD22 Chimeric Antigen Receptor T-Cell Therapy.J Immunother · 201879 citationsRCR 2.5
- CD22 CAR T cells demonstrate high response rates and safety in pediatric and adult B-ALL: Phase 1b results.Leukemia · 202450 citationsRCR 5.3